Tag:
Nycomed
Latest Headlines
Latest Headlines
NPS Pharma goes global with $80M deal to buy back Takeda's Gattex rights
NPS Pharmaceuticals has locked up the global rights to Gattex. The biotech bought back the ex-U.S. rights to its newly approved orphan drug (teduglutide) alongside another drug program close to a U.S. filing for rare cases of hypoparathyroidism, handing over $50 million in stock--a 7% equity stake in the company--with another $30 million on the table if the company hits a key sales milestone.
Ariad lands Jonathan E. Dickinson as general manager, Europe
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Jennifer Levin ( email | Twitter ) and we will feature it...
Ex-Nycomed chief to take chairman's seat at Lundbeck
Björklund had been CEO at the Swiss drugmaker Nycomed, until it sold out to Takeda Pharmaceuticals in 2011.
Private equity's pharma hopes exemplified by Nycomed
If you've ever wondered why private equity investors are such big buyers and sellers in the pharma world, look no further than Nycomed . As Forbes explains, Nordic Capital, a small Swedish firm...
EC antitrust squad drops AZ-Nycomed probe
AstraZeneca ( $AZN ) and Nycomed are in the clear, at least as far as European regulators are concerned. The European Commission's antitrust squad has dropped an investigation of the two companies...
Wyeth puts $960M squeeze on Sun for Protonix launch
Sun Pharmaceuticals ' at-risk launch of generic Protonix may prove to have been risky indeed. Pfizer's ( $PFE ) Wyeth unit slapped the Indian drugmaker with a $960 million damages claim, alleging Sun's
Astellas scores highest in Japanese M&A bout
Japan’s biggest pharma players have been roaming the world in recent years in a restless search for new acquisitions. They've been looking for deals to put an extra oomph into their earnings.
Takeda abandons Euro rights to Durect's controlled-release pain drug
For the second time this year, Durect ($DRRX) faces a setback over its controlled-release anti-pain drug Posidur. The Cupertino, CA-based company disclosed that its European development and marketing
Takeda to ax 2,800 workers, consolidate R&D in global restructuring
Four months after closing its $14 billion Nycomed buyout, Japan's Takeda says it will take an ax to its R&D operations as it sheds 2,800 employees. Most of the layoffs will occur in Europe, with
Takeda's plate full with Nycomed integration
Takeda Pharmaceutical says its $13.7 billion acquisition of Nycomed is enough to digest for now. Despite the strong yen, which has been fueling Japanese companies' buyouts abroad, Takeda President
